For instance, overexpression of EGFR and DNA mutations in the extracellular and intracellular portions of the protein have been observed in 43–89% of cases of non-small-cell lung carcinoma (NSCLC) [70], which makes this receptor a relevant target in NSCLC treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.